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We have previously developed a mouse model of insu-
lin-resistant diabetes by targeted inactivation of the in-
sulin receptor gene. During studies of gene expression
in livers of insulin receptor-deficient mice, we identified
a novel cDNA, which we have termed sirm (Son of Insu-
lin Receptor Mutant mice). sirm is largely, albeit not
exclusively, expressed in insulin-responsive tissues. In-
sulin is a potent modulator of sirm expression, and sirm
mRNA levels correlate with tissue sensitivity to insulin.
The product of the sirm gene is a serine/threonine-rich
protein with several proline-rich motifs and an NPNY
motif, conforming to the consensus sequence recognized
by the phosphotyrosine binding domains of insulin re-
ceptor substrate and Shc proteins. However, Sirm bears
no extended homologies with other known proteins.
Based on the sequences of the proline-rich domains, we
sought to determine whether Sirm binds to the SH3
domains of FYN and Grb-2. We demonstrate here that
Sirm binds to FYN and Grb-2 in 3T3-L1 adipocytes and
that insulin treatment results in the dissociation of the
SirmzFYN and SirmzGrb-2 complexes. We also show that
Sirm is a substrate for the kinase activity of FYN in
vitro. Based on the patterns of expression of sirm, its
regulation by insulin, and the interactions with mole-
cules in the insulin signaling pathway, we surmise that
Sirm plays a role in modulating tissue sensitivity to
insulin.
We have previously developed a mouse model of insulin-
resistant diabetes by genetic ablation of insulin receptors. Lack
of insulin receptors is rapidly lethal, leading to death from
diabetic ketoacidosis within few days of birth (1, 2). We have
reported that insulin treatment of liver extracts derived from
insulin receptor-deficient (ir2/2)1 mice resulted in tyrosine
phosphorylation of a protein migrating as a 75-kDa species on
SDS-PAGE. This protein was not detected in control (ir1/1
mice) liver extracts. In the course of experiments designed to
determine the identity of this tyrosine-phosphorylated protein,
we isolated a novel cDNA. We termed the protein product of
this cDNA sirm (Son of Insulin Receptor Mutant mice). sirm
mRNA is most abundant in insulin-sensitive tissues, such as
skeletal muscle, heart, fat, kidney, and liver, and is regulated
by insulin both in vivo and in cultured cells. In fact, sirm
mRNA expression correlates with insulin sensitivity so that it
is increased under conditions of increased insulin sensitivity,
for example during differentiation of 3T3-L1 cells and in dia-
betic ketoacidosis, and is decreased under conditions of desen-
sitization to insulin, for example following prolonged exposure
of cells to insulin. We have cloned a 3661-base pair sirm cDNA.
The amino acid sequence predicted from sirm cDNA clones
encodes a 600-amino acid polypeptide, bearing no extended
homology to other known proteins. The Sirm protein is rich in
serine and threonine residues and contains potential sites for
tyrosine phosphorylation and for phosphorylation by proline-
directed kinases, as well as proline-rich motifs. Immunoreac-
tive Sirm localizes exclusively to the cytoplasm in skeletal
muscle, whereas it is found partly associated with the mem-
brane compartment in 3T3-L1 adipocytes. We show, using co-
immunoprecipitation studies and GST binding assays, that
Sirm binds to the SH3 domains of FYN and Grb-2 in vitro and
in cultures of 3T3-L1 cells. Insulin treatment results in the
dissociation of the SirmzGrb-2 and SirmzFYN complexes. Sirm
also appears to be a substrate for phosphorylation by the FYN
kinase. The engagement of Sirm in complex formation with
adapter proteins and cytoplasmic tyrosine kinases, together
with the distribution of Sirm to insulin-dependent tissues, and
the regulation of sirm mRNA by insulin both in vivo and in
vitro represent circumstantial evidence for the fact that Sirm
plays a role in modulating tissue sensitivity to insulin.
EXPERIMENTAL PROCEDURES
Animals—Husbandry and genotyping of mice bearing a targeted ir
allele have been described in previous publications (2–4).
Antibodies—Anti-phosphotyrosine antibody 4G10 was purchased
from Upstate Biotechnology (Lake Placid, NY). Anti-insulin receptor
antibodies were purchased from Oncogene Science (Cambridge, MA)
and Santa Cruz Biotechnology (Santa Cruz, CA). Anti-FYN and anti-
Grb-2 antibodies were purchased from Santa Cruz. Anti-Sirm antisera
were raised by immunizing rabbits with keyhole limpet hemocyanin-
conjugated peptides corresponding to amino acids 136–149 of the Sirm
sequence. All antisera were affinity purified using peptide columns. For
immunoprecipitation, antibodies were used at the concentrations rec-
ommended by the manufacturers. The immune complexes were cap-
tured on protein A-agarose beads (Life Technologies, Inc.) and washed
three times in 1.0 ml of 50 mM HEPES, 150 mM NaCl, 0.1% Triton X-100
buffer and analyzed by SDS-polyacrylamide electrophoresis. The pro-
teins were transferred to nitrocellulose filters for Western analysis.
Blots were pre-blocked in 3% BSA in PBS and incubated with the
anti-Sirm antibodies at a 1:1000 dilution in 0.3% BSA in PBS for 2 h at
room temperature. Following a short wash in PBS containing 0.05%
Tween 20 and 0.05% Triton X-100, a horseradish peroxidase-conjugated
goat anti-rabbit antibody (Bio-Rad) was added at a 1:5000 dilution and
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incubated for 20 min. Three additional washes were performed in
PBS/Tween/Triton, followed by detection of chemiluminescence using
ECL (Amersham Corp.).
RNA Analysis—Total RNA was isolated from mouse livers and hind
limb skeletal muscles or from SV40-transformed hepatocytes using a
guanidinium isothiocyanate/acid phenol extraction procedure. Reverse
transcription-PCR was performed as described previously. PCR condi-
tions were as follows: denaturation at 94 °C for 1 min, annealing at
45 °C for 1 min, and extension at 72 °C for 1 min for 30 cycles. PCR
products were analyzed by gel electrophoresis. For Northern analysis,
poly(A)1-enriched RNA was obtained by oligo-(dT) affinity chromatog-
raphy. 2–3 mg of poly(A)1 RNA were size-fractionated on denaturing 1%
agarose, 2.2 M formaldehyde gels and transferred to nitrocellulose mem-
branes. The filters were probed with random-primed sirm cDNA. Ad-
FIG. 1. A, alignment of mouse IGF-1 receptor and sirm sequences. This figure shows the partial homology between the primers used to screen
for IGF-1 receptor-related sequences and the sirm sequence. There is 66 and 57% identity between the upstream and downstream IGF-1 receptor
primers and the relevant sirm sequences. Of note is also the virtual identity (10 out of 11 matches) at the 39 end of the upstream primer. B,
schematic diagram of the Sirm protein and cloning strategy. Represented from top to bottom: *, a diagram of the Sirm protein with potential
tyrosine phosphorylation sites; ‡, proline-directed serine phosphorylation sites; vertical bars, proline-rich sequences; a diagram of the GST-Sirm
used for in vitro phosphorylation assays; the location of the peptide used to raise antibodies; a diagram of the cDNA clone, horizontal bar, the
sequence of which is shown in C, with the location of the coding sequence; the location of Marathon cDNA clones used to obtain the 59 and 39 end
of the coding sequence; the cDNAs isolated from library screening and RT-PCR; the original sirm PCR product, with the primers used to identify
sirm; and the in vitro translation product of the sirm cDNA. The sequence of the PCR primers is reported in A. The sequence NPNY (amino acids
34–37) is indicated above the bar. C, sequence of mouse sirm complementary DNA. A consensus sequence was developed using the Autoassembler
software from a combination of cloned cDNA clones and amplified products from Marathon-ready cDNA. The translation start and stop codons, the
putative polyadenylation signals, and some of the major structural motifs are indicated in bold.
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ditionally, a mouse multiple tissue, an embryonic Northern blot, as well
as a zoo blot (CLONTECH, Palo Alto, CA) were used to confirm the
identity of the various clones isolated, to study the distribution of the
sirm transcripts, and to analyze the presence of sirm gene homologues
in other species. Hybridization was performed according to standard
procedures.
Cloning of Full-length Sirm cDNA—Initially, a random primed sirm
fragment obtained by RT-PCR amplification of ir2/2 liver RNA was
used to probe 106 plaques of mouse embryo and mouse fetal heart cDNA
libraries (CLONTECH). Hybridization and plaque purification of indi-
vidual positive clones were carried out according to standard methods.
However, only partial cDNA clones could be isolated from these librar-
ies. To isolate full-length clones, mouse heart Marathon-ready cDNA
(CLONTECH) was amplified using primers derived from the 59 and 39
end of the available sequence. Amplification was carried out as sug-
gested by the manufacturer, with a mixture of Klenow and Taq polym-
erase. Amplified products were subcloned into a PCR II vector (Invitro-
gen, Carlsbad, CA) and sequenced using cycle sequencing with
fluorescent dideoxy terminators (Applied Biosystems, Foster City, CA)
on 373 and 377 Applied Biosystems sequencers. Each partial clone was
hybridized with multiple tissue Northern blots as well as Northern
blots of ir2/2 mice to confirm that amplified sequences derived from the
same original transcripts. Multiple subcloned fragments were analyzed
to confirm the nucleotide sequence. Sequence alignment was carried out
FIG. 1—continued
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using the Autoassembler software (Applied Biosystems) to develop a
consensus sequence. Ambiguities were further resolved by visual in-
spection of electropherograms.
Expression of GST-sirm Fusion Products—An 1800-nt fragment of
the mouse sirm cDNA was amplified from Marathon-ready mouse heart
cDNA. The upstream primer 59 GAA TTC TCC AGC TGG CAC ATG
AAC AAC AGT39 (nt 949–972) contained an additional EcoRI site in
frame with the ATG initiation codon (bold face). The downstream
primer spanned nt 2924–2901. The amplified product was digested
with EcoRI to generate a 1590-nt fragment, which was subsequently
subcloned into the EcoRI site of pGEX2T (Pharmacia Biotech Inc.). The
amplified fragment was entirely sequenced to rule out nucleotide sub-
stitutions during the amplification procedure. Bacterial cultures were
obtained as indicated by the manufacturer, and the recombinant GST-
Sirm fusion protein was isolated by affinity chromatography using
glutathione-Sepharose beads.
Tissue Isolation—Whole E13.5 and 18.5 mouse embryos, or livers,
hind limb muscles, hearts, epididymal fat pads, and kidneys derived
from adult mice were finely minced and homogenized using a glass-
glass pestle in 1 mM NaHCO3 containing a mixture of protease inhibi-
tors (Boehringer Mannheim). 20 mg of whole tissue extracts were pre-
pared for SDS-gel electrophoresis as described (2).
Subcellular Fractionation—In some experiments, subcellular frac-
tions were obtained from cultures of 3T3-L1 cells or from mouse skeletal
muscle. After resuspending the cells or tissue in 1 mM NaHCO3 buffer
as described above, nuclei were removed by a low speed centrifugation
(1000 3 g) for 10 min, followed by high speed centrifugation (20,000 3
g) to pellet the microsomal fraction and separate the cytosol. The crude
microsomal homogenate was solubilized in 50 mM HEPES (pH 7.6) 150
mM NaCl containing 1% Triton X-100 and protease inhibitors, followed
by centrifugation at 100,000 3 g to remove the insoluble material.
Insulin Stimulation of 3T3-L1 Cells and SV40-transformed Hepato-
cytes—3T3-L1 cells were differentiated as described (5). Cultures of
differentiated 3T3-L1 cells or confluent SV40-transformed hepatocytes
derived from ir2/2 mice or from ir1/1 mice were grown in 100-mm Petri
dishes as described. Following incubation overnight in 1% dialyzed fetal
bovine serum (3T3-L1) or for 4 h in 1% insulin-free BSA (SV40-trans-
formed hepatocytes), cells were incubated in the presence or absence of
100 nM insulin for various lengths of time at 37 °C. Thereafter, cells
were frozen in liquid N2 and thawed in solubilization buffer (1% Triton
X-100 in 50 mM HEPES, 150 mM NaCl, 100 mM NaF, 4 mM sodium
orthovanadate, 1 mM EDTA, 4 mM sodium pyrophosphate). For RNA
analysis studies, SV40-transformed hepatocytes were incubated with
insulin (1 or 100 nM) for 4 h, frozen in liquid N2, and thawed for RNA
extraction as outlined above.
In vitro transcription/translation was performed using a coupled
rabbit reticulocyte system (Promega, Madison WI) according to the
manufacturer’s instructions.
GST Fusion Protein Binding Assay—The GST fusion proteins used in
these studies are as follows: mouse c-Abl type IV SH3 domain (amino
FIG. 2. Alignments of Sirm proline-
rich domains with consensus motifs
that bind the SH3 domains of FYN
and Grb2. A, consensus sequences for
class I and class II SH3 binding; B, align-
ment of two potential SH3 binding do-
mains (amino acids 231–240 and 332–
337) in the Sirm sequence with the
consensus Src, FYN, and Grb2 SH3 bind-
ing sites. C, alignment of the proline-rich
domain encoded by amino acids 231–240
of Sirm with the SH3 binding domains of
CR16 (15), SH3 BP-2 (16), Ras GAP-SH3
(17), and Abi-2 (18).
FIG. 3. Sirm mRNA levels are increased in mice lacking insulin
receptors. RNAs were isolated from newborn mouse muscle (lanes 1–3)
and liver (lanes 4–6). The blot was hybridized with a sirm cDNA and
reprobed with an actin probe to normalize for RNA content. Scanning
densitometry was employed to quantitate levels of sirm mRNA. Quan-
titative representation of the data is presented at the bottom of the
figure. In each set of tissues, the highest levels of sirm mRNA were
normalized to 100%. For each lane, RNAs from 3 to 5 animals were
pooled. 2 mg of poly(A)1 were applied to lanes 1–3, whereas 3 mg of
poly(A)1 were applied to lanes 4–6.
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acids 84–138) (6), the mouse phosphatidylinositol 3-kinase p85 SH3
domain (amino acids 1–80) (7), the human FYN SH3 domain (amino
acids 84–148) (8), and the full-length mouse Grb2 (Upstate Biotechnol-
ogy). Confluent monolayers of SV40-transformed hepatocytes (in two
175-cm2 flasks) were solubilized in 5 ml of 1% Triton buffer. 5 mg of
recombinant GST fusion protein in 0.05 ml were added to the extracts
and allowed to bind for 1 h at 4 °C on a rotating wheel. Thereafter, the
material was pelleted by centrifugation and washed in 10 ml of 0.1%
Triton buffer four times. The final pellet was prepared for electrophore-
sis as described above.
In Vitro Kinase Activity—2 units of purified FYN kinase (Upstate
Biotechnology) were incubated with 1 unit of denatured rabbit muscle
enolase (Sigma) in the presence of GST, or GST-Sirm, or with various
concentrations of peptides corresponding to Sirm amino acid sequences
224–246 (peptide 1), 331–339 (peptide 2), and 29–40 (peptide 3). There-
after, a phosphorylation buffer containing 50 mM HEPES (pH 7.4), 5 mM
MgCl, and 10 mCi of [g-32P]ATP (3000 Ci/mmol, NEN Life Science
Products) was added, and the reaction was incubated at room temper-
ature for 30 min. The reaction was stopped by adding Laemmli sample
buffer, and the products were analyzed by SDS-PAGE followed by
autoradiography. One of two experiments is shown.
RESULTS
Cloning of Sirm—We had previously shown that insulin
stimulation of liver extracts derived from ir2/2 mice results in
tyrosine phosphorylation of a protein of apparent mass of ;75
kDa that is not observed in ir1/1 mice (see Fig. 3B in Ref. 2). We
questioned whether this protein may share sequence similarity
with the insulin receptor or its substrates. To this end, we
carried out RT-PCR amplification from ir2/2 and ir1/1 mice
liver RNA using several sets of primers, the sequences of which
were derived from mouse insulin and IGF-1 receptors, as well
as insulin receptor substrate-1 (IRS-1). A set of primers de-
signed to amplify the extracellular domain of the IGF-1 recep-
tor consistently gave rise to an additional band of slightly
larger size than predicted (Fig. 1A). This band was unique to
ir2/2 liver RNA and was never observed in amplification ex-
periments with ir1/1 mouse liver RNA (data not shown). The
band was isolated, sequenced, and used as a hybridization
probe to isolate clones containing the sirm coding sequence. By
using a combination of cDNA library screening and cDNA
amplification techniques, we cloned a 3661-nt cDNA, with an
open reading frame of 1800 nucleotides, predicted to encode a
600-amino acid polypeptide. The 59 end of the cDNA was iso-
lated from mouse heart Marathon cDNA (CLONTECH). Two
different clones were isolated, possibly as the result of two
different transcription start sites. The longest cDNA contains
962 nt of 59-untranslated sequence; the shorter one contains
620 nt. Two non-canonical ATTAAA polyadenylation signals
are found 24 and 160 nt downstream of a putative ochre ter-
mination codon. In vitro translation of a full-length sirm cDNA
clone in a rabbit reticulocyte lysate yielded a peptide of 81 kDa
(Fig. 1B).
The predicted amino acid sequence of Sirm (Fig. 1C) bears weak
homology (20% identity in a 511-amino acid overlap) to the KSP
region of the unc-89 gene product in Caenorhabditis elegans (9) and
FIG. 4. Insulin treatment decreases steady-state sirm mRNA
levels. Confluent monolayers of SV40-transformed murine hepatocytes
derived from ir1/1 (lanes 1–3) or ir2/2 mice (lanes 4–6) were incubated
in the presence of the indicated concentrations of insulin for 4 h.
Thereafter, RNA was extracted and analyzed by Northern blot. The
upper panel shows the result of hybridization with a sirm cDNA probe,
whereas the middle panel shows the control hybridization with an actin
probe. A densitometric analysis of the intensity of the bands, corrected
for actin RNA, is plotted in the bottom panel. Sirm mRNA levels in
untreated cells are normalized to 100%.
FIG. 5. Tissue survey of sirm mRNA
expression. Mouse multiple tissue and
embryonic Northern blots (CLONTECH)
and a blot containing RNA derived from
undifferentiated and differentiated 3T3-L1
cells were hybridized with a sirm cDNA
as indicated in Fig. 2, A and B. The panel
on the bottom right side shows the result
of a control hybridization with actin of the
3T3-L1 blot, to demonstrate the presence
of RNA from undifferentiated cells.
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to the open reading frame K08E7.5 on chromosome IV of C. elegans
(21% identity in a 598-amino acid overlap) (10). The KSP region of
the unc-89 gene is serine- and threonine-rich and is thought to
represent a potential target for phosphorylation by cell cycle-de-
pendent kinases. We did not detect any homology to known mam-
malian proteins. However, analysis of the data base of expressed
sequence tags revealed that sirm is virtually identical to two hu-
man ESTs. The first EST corresponds to a skeletal muscle cDNA
(Z19503/HSB35G062); the second one to a beta cell library cDNA
(T10445) (11).
The longest sirm open reading frame is predicted to encode a
polypeptide of 69,000 Da (Fig. 1C). Hydropathy profile analysis
indicates that Sirm lacks a hydrophobic sequence long enough
to serve as a transmembrane domain. The sequence is enriched
in serines and threonines (20% of all amino acids) and in basic
residues (17% arginines, lysines, and histidines). There are five
potentialOSPO phosphorylation sites by proline-directed ser-
ine kinases at amino acid residues 76, 189, 231, 418, and 438.
Three potential sites of tyrosine phosphorylation are present at
positions 37, 56, and 81. Tyr37 is of interest in that it conforms
to an NPXpY motif found in receptor tyrosine kinases and is
thought to serve as a binding site for the phosphotyrosine
binding domains of IRS and Shc molecules upon phosphoryla-
tion (12). Another interesting feature of Sirm is the presence of
four proline-rich motifs, conforming to the SH3 binding consen-
sus PXXP (13). Of these, sequences NPLPTTPKR (amino acids
328–336) and PLPLLPSK (amino acids 240 to 233, in reverse
orientation) share homology with the Src and Grb2 SH3 con-
sensus binding site RPLPPLP (14) (Fig. 2B). The sequence
between amino acids 224 and 246 conforms to a consensus
PCXXSPLLPXPXP sequence, where C indicates a hydrophobic
amino acid, found in the following four known SH3 domain-
binding proteins: CR16, a protein encoded by a brain-specific
mRNA regulated by glucocorticoids (15); SH3 BP2, a protein
FIG. 6. A, tissue distribution of immunoreactive Sirm protein. Different mouse tissues, indicated on the top, were solubilized in NaHCO3 buffer
containing protease inhibitors. 15 mg of proteins were applied to the lanes containing muscle, heart, fat, and embryo extracts; 40 mg were applied
to the lanes containing liver and kidney extracts. Proteins were separated by SDS-PAGE and transferred to nitrocellulose filters. The filters were
incubated with anti-Sirm antibody (left panel) in the absence or presence of 1 mM competing peptide (middle panel). Preimmune serum was also
used as control and is shown in the right-hand panel. B, subcellular localization of Sirm. Tissue extracts of mouse skeletal muscle and 3T3-L1
adipocytes were fractionated into a cytosolic and a membrane-enriched fraction (see “Experimental Procedures”). As a control, nuclei (nuc) were
collected by low speed centrifugation during the preparation of muscle extracts and are shown in the 1st two lanes on the left. The amounts of
protein extracts applied were the following: 15 mg of muscle nuclei, 15 mg of muscle and 3T3-L1 membrane (m) and cytosol (c), 40 mg of liver cytosol
(ir1/1 mice), 80 mg of liver cytosol (ir2/2 mice), 10 mg of heart cytosol (ir1/1 mice), and 16 mg of heart cytosol (ir2/2 mice). Proteins from each fraction
were analyzed by SDS-PAGE followed by immunoblotting with anti-Sirm antibody. WT, wild-type
FIG. 7. Association of Sirm with Grb2 and with SH3 domains of p85a, Abl, and FYN. Left panel, GST fusion proteins encoding the SH3
domains of Abl, FYN, p85, the entire Grb2 coding sequence, or wild-type GST (5 mg) were incubated with Triton extracts of SV40-transformed
murine hepatocytes (SV40-hep). The resulting pellets were immunoblotted with an anti-Sirm antibody. Right panel, in vitro translated Sirm
protein (as shown in Fig. 1B) was incubated with the same amount of Abl, Grb2, FYN, and wild-type GST fusion protein as shown in the left panel,
in the absence or presence of 1 mM competing peptide. The peptide sequences are as follows: peptide 1, IPLLKSPLLPLPTPKS; peptide 2,
NPLPTTPKR.
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that binds to the Src, Nck, Grb-2, and Abl SH3 domains (16);
the Ras-GAP SH3 binding protein (17); and Abi-2, a protein
cloned based on its ability to bind with high affinity to the SH3
domain of Abl (18). It should be noted, however, that the
proline-rich domains of SH3 BP-2 and Abi-2 that are homolo-
gous to Sirm are not the same as those implicated in Abl
binding (16, 18).
sirm mRNA Is Overexpressed in Liver and Skeletal Muscle of
Mice Lacking Insulin Receptors—sirm was originally detected
in RNA derived from ir2/2 mice. Next, we asked whether fail-
ure to detect sirm in the same assay in ir1/1 mice could be due
to overexpression of sirm in ir2/2 mice compared with normal
littermates. Northern blotting analysis was performed on
pooled RNAs derived from skeletal muscle and liver of three to
five ir1/1, ir1/2, and ir2/2 mice (Fig. 3). In liver of ir2/2 mice,
sirm mRNA levels were 3-fold higher than in ir1/1 mice (Fig. 3,
lanes 4 and 6) after correcting for the amount of actin mRNA
(lower panel), whereas in skeletal muscle they were 40% higher
(lanes 1 and 3). Intermediate variations were observed in ir1/2
mice (lanes 2 and 4).
Expression of Sirm Correlates with Tissue Sensitivity to In-
sulin—To determine further whether expression of sirm is
under regulation by insulin, we studied the effect of insulin on
sirm expression in SV40-transformed hepatocytes derived from
ir2/2 and ir1/1 mice. Cells derived from ir2/2 mice are devoid of
insulin receptors but possess about 50,000 IGF-1 receptors/
cell.2 After treatment with insulin (1 or 100 nM), RNA was
isolated and analyzed by Northern blotting with a 32P-labeled
sirm cDNA (Fig. 4). 4 h treatment of normal cells with 1 nM
insulin led to a 50% decrease of sirm expression, and 100 nM
insulin led to a 90% decrease (Fig. 4, lanes 1–3). In contrast, in
ir2/2 cells, 1 nM insulin decreased sirm mRNA levels by 20%
and 100 nM insulin by 45% (Fig. 4, lanes 4–6). Thus, expression
of the sirm gene is decreased following prolonged exposure of
cells to insulin. The ID50 for insulin inhibition of sirm expres-
sion is ;1 nM in ir1/1 cells and ;100 nM in ir2/2 cells. This
observation suggests that insulin regulates sirm expression in
ir2/2 cells by binding to IGF-1 receptors. In fact, insulin would
be predicted to bind to IGF-1 receptors with about 100-fold
lower affinity compared with insulin receptors.
Sirm Is Prevalently Expressed in Insulin-responsive Tis-
sues—We performed a tissue survey of sirm gene expression
(Fig. 5). During mouse embryonic development, sirm expres-
sion peaks in mid-late gestation (E11–15), to then decline prior
to birth (left panel). In adult mouse, sirm is most abundant in
skeletal muscle and heart (Fig. 5, middle panel). Additionally,
sirm is expressed in kidney, brain, and lung. Although not
clearly visible on this exposure of the blot, sirm mRNA can be
detected in liver, as demonstrated in Figs. 3 and 4. Expression
of sirm is associated with adipocyte differentiation of 3T3-L1
cells (Fig. 5, right panel). Furthermore, sirm is identical to EST
T10445, which was isolated from a pancreatic islet library (11,
19). Thus, sirm is expressed in virtually all insulin-responsive
tissues and, at lower levels, in other organs. Similar expression
patterns were detected using Northern analysis of human
RNAs (data not shown). A zoo blot (CLONTECH) was hybrid-
ized to a 32P-labeled mouse sirm cDNA. Results indicate that
homologues of the mouse sirm gene are present in human, rat,
and yeast (data not shown).
Subcellular Distribution of Sirm and Quantification of the
Protein Product in Mice—We raised a polyclonal antserum
against the peptide sequence corresponding to amino acids
136–149 of Sirm. The antiserum detected an immunoreactive
species of ;90 kDa in several mouse tissues, which is specifi-
cally competed by the peptide used for affinity purification of
the antiserum (Fig. 6A, compare left and middle panel). The
same band is not present when preimmune serum is used for
immunoblotting (Fig. 6A, right panel). The tissue distribution
of immunoreactive Sirm protein correlates well with patterns
of mRNA expression.
We next examined the subcellular localization of Sirm (Fig.
6B). Extracts of skeletal muscle and 3T3-L1 adipocytes were
separated into cytosolic and membrane-enriched fractions. In
skeletal muscle, immunoreactive Sirm was detected exclu-
sively in the cytosolic fraction. In contrast, in 3T3-L1 adipo-
cytes, a fraction of Sirm immunoreactivity corresponding to
about 25% of the total was membrane-associated (Fig. 6B).
Short term (5 min) stimulation with 100 nM insulin did not
affect the subcellular distribution of Sirm (Fig. 6B, compare
2insulin and 1insulin lanes).
We also compared the levels of Sirm immunoreactivity in
livers and hearts of ir1/1 and ir2/2 mice (Fig. 6B, compare WT
and 2/2 lanes), but we failed to detect the difference predicted
on the basis of the Northern blot shown in Fig. 3. It is possible
that the discrepancy between levels of mRNA and immunore-
activity is due to impaired recovery of immunoreactive Sirm
protein in insulin receptor-deficient mice caused by their ad-
vanced metabolic derangement.
Sirm Binds to Grb-2 and to the SH3 Domain of FYN in
Vitro—The amino acid sequence of Sirm contains four proline-
rich domains that could potentially serve as binding sites for
SH3-containing proteins. Based on the homology between
these domains and the known binding specificities of Grb-2 and
FYN (Fig. 2B), we investigated whether Sirm could bind to
Grb-2 or FYN SH3-GST fusion proteins in vitro. Furthermore,
in view of the consensus sequence among Sirm (amino acids
224–246) and several Abl-binding proteins, we also included
the Abl SH3-GST protein in these experiments, as well as the
p85a SH3-GST as a negative control. GST fusion proteins
containing the SH3 domains of the p85a subunit of phosphati-
dylinositol 3-kinase (7), Abl (6), FYN (8), and full-length Grb-2
were expressed in Escherichia coli, purified, and incubated
with detergent extracts of SV40-transformed hepatocytes. Im-
munoblotting of the resulting gels with the Sirm antibody
showed that Sirm binds to GST-Grb2 and GST-FYN SH3 but
not to the SH3 domains of p85a or Abl (Fig. 7, left panel). To
characterize better the nature of this interaction, we incubated
in vitro translated Sirm with GST fusion proteins in the ab-
sence or presence of two proline-rich peptides derived from the
Sirm sequence (Fig. 7, right panel). Sirm binding to Grb-2 was2 K. Rother, Y. Imai, and D. Accili, manuscript in preparation.
FIG. 8. Sirm binds to FYN and Grb-2
in 3T3-L1 cells. Detergent extracts of
undifferentiated or differentiated 3T3-L1
cells were incubated with various anti-
bodies, as indicated on the top of each
panel. Thereafter, the immune complexes
were centrifuged for 5 min at 14,000 rpm
and washed as described under “Experi-
mental Procedures.” The samples were
prepared for electrophoresis and analyzed
by immunoblotting with an anti-Sirm
antibody.
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inhibited by incubating extracts in the presence of the proline-
rich peptide IPLLKSPLLPLPTPKS (peptide 1, Fig. 7) but not
by peptide NPLPTTPKR (peptide 2 Fig. 7), whereas binding to
FYN SH3 was inhibited by both peptides, indicating that, at
least in this reconstitution experiment, Sirm can interact with
Grb-2 and FYN directly, through one (Grb-2) or more (FYN)
proline-rich sequences (Fig. 2).
Sirm Binds to Grb-2 and FYN in 3T3-L1 Cells—Insulin
treatment dissociates the sirmzGrb-2 and sirmzFYN complexes.
Next, Sirm binding to SH3 domain proteins was investigated in
cultures of 3T3-L1 cells. We questioned whether the association
between Sirm and Grb-2 or FYN could be detected in vivo by way
of co-immunoprecipitation assays (Fig. 8). As shown in A, Sirm
expression is greatly increased following differentiation of 3T3-L1
cells and is decreased by ;30% by treatment with 100 nM insulin
for 30 min. Following immunoprecipitations with the various anti-
bodies, proteins bound to the immune complexes were analyzed by
SDS-PAGE and immunoblotting with anti-Sirm antibody. Follow-
ing immunoprecipitation with FYN antibody (Fig. 8B), immunore-
active Sirm could be detected in differentiated 3T3-L1 cells under
basal conditions. However, insulin treatment resulted in the com-
plete disappearance of FYN-bound Sirm, indicating that FYN is
indeed complexed with Sirm in 3T3-L1 cells and that insulin treat-
ment causes dissociation of the SirmzFYN complexes. Likewise,
Sirm could be detected in Grb-2 immunoprecipitates under basal
conditions but not following insulin treatment (Fig. 8C). No Sirm
immunoreactivity is present following immunoprecipitation with
nonimmune serum (Fig. 8D). Control immunoblotting experiments
with Grb-2 and FYN antibodies indicate that the same amount of
protein is present in all lanes (not shown).
Sirm Is a Substrate for the Kinase Activity of FYN in Vitro,
the Failure of Sirm to Modulate FYN Kinase—The activity of
Src family kinases, such as FYN, is regulated through interac-
tions of cellular proteins with their SH2 and SH3 domains. For
example, deletion of either domain leads to constitutive activa-
tion of the Abl or Src kinases (20–22). We wanted to determine
whether Sirm could modulate FYN kinase activity through
SH3 domain interactions. GST-Sirm (amino acids 1–535) was
incubated with partially purified FYN and [g-32P]ATP (Fig. 9),
and the kinase activity of FYN was measured using enolase as
a substrate in the presence or absence of various concentra-
tions of the two proline-rich peptides that interact with FYN
(Fig. 9, lanes 4–9). Neither GST-Sirm (amino acids 1–535) nor
Sirm-derived peptides altered phosphorylation of enolase by
FYN. Furthermore, FYN catalyzed the phosphorylation of
GST-Sirm (lane 3). We have also shown that Sirm can serve as
a substrate for the insulin and IGF-1 receptor tyrosine kinases
in vitro (not shown).
DISCUSSION
In this paper, we report the identification and a preliminary
characterization of a novel gene, which we have termed sirm.
Even though the identification of sirm was the serendipitous
by-product of a search to identify proteins uniquely expressed
by insulin receptor-deficient mice, several features of the sirm
gene prompted us to investigate it further. First, insulin is a
potent regulator of sirm mRNA expression, so that sirm mRNA
is up-regulated in conditions of increased tissue sensitivity to
insulin, such as differentiation of 3T3-L1 cells and diabetic
ketoacidosis, whereas it is down-regulated by prolonged insulin
treatment. Interestingly, the highest levels of sirm expression
are found in insulin-sensitive tissues, such as skeletal muscle,
heart, fat, kidney, and liver. Indirect evidence indicates that
sirm is also expressed in pancreatic beta cells, since an EST
with virtual sequence identity to sirm was detected in a beta
cell library (11). Interestingly, we have localized the human
homologue of sirm to chromosome 15q15, in the genetic inter-
val between D15S118 and D15S123, which corresponds to
32–45 centimorgans on the physical map of chromosome 15.3
This region contains marker D15S102. In studies of Mexican
American sibling pairs with non-insulin-dependent diabetes
mellitus, Hanis et al. (23) reported a significant departure from
the expected frequency of allele sharing at this marker. Fur-
ther studies will be necessary to determine whether this region
contains a diabetes-susceptibility locus; however, the co-local-
ization of SIRM to this region is intriguing.
The sequence of Sirm contains a number of interesting fea-
tures that suggest clues as to its function. In this paper, we
have shown that Sirm can interact with proteins containing
SH3 domains through its proline-rich motifs. In 3T3-L1 cells,
Sirm associates with the Src family tyrosine kinase FYN. Bind-
ing of Sirm to FYN was predicted on the basis of a consensus
binding site for the FYN SH3 domain (Fig. 2B) (14, 24). Inter-
estingly, insulin treatment leads to complete dissociation of
Sirm from FYN. The binding of Sirm to FYN is intriguing, in
view of the fact that FYN has been implicated in adipocyte-
specific functions of insulin and particularly in the mechanism
whereby insulin stimulates phosphorylation of caveolin in
3T3-L1 cells (25, 26). Caveolin is an important component of
caveolae, flask-shaped invaginations of plasma membranes,
which are thought to participate in the processing of intracel-
lular signals. Some workers (27) have also reported that caveo-
lae contain adapter molecules like Grb-2, which also binds to
Sirm. It remains to be determined whether Sirm co-localizes
with FYN in caveolae; however, it is interesting that a signif-
icant fraction of cellular Sirm is associated with the plasma
membrane in 3T3-L1 adipocytes. Work from the Saltiel labo-
ratory (26) has suggested that Cbl is the kinase responsible for
stimulating the adipocyte-specific caveolin kinase activity of
FYN. FYN kinase is activated by binding of cellular proteins to
its SH2 and SH3 domains. Thus, an appealing possibility was
that Sirm would regulate the FYN kinase in an adipocyte-
specific fashion. We have failed to demonstrate that Sirm or
peptides derived from it can modulate the kinase activity of
FYN toward enolase. While these findings do not entirely rule
out that Sirm may modulate the FYN kinase in vivo, they are
consistent with data of Mastick et al. (26), suggesting that the
kinase activity of FYN is not different in differentiated 3T3-L1
3 Y. Kido, and D. Accili, manuscript in preparation.
FIG. 9. Sirm is a substrate for the in vitro kinase activity of
FYN. Purified FYN kinase was incubated with denatured enolase (lane
1) and GST (lane 2) or GST-sirm (lane 3), or with various concentrations
of proline-rich peptides 1 (corresponding to the sequence 224–246), 2
(corresponding to the sequence 331–339), and with a control peptide
(corresponding to the sequence 29–40). Thereafter, a phosphorylation
mixture containing MgCl and [g-32P]ATP was added, and the reaction
was incubated at room temperature for 30 min. The reaction products
were analyzed by SDS-PAGE followed by autoradiography. One of two
experiments is shown.
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cells compared with their undifferentiated counterpart. On the
other hand, the identification of Sirm as an adipocyte-specific
substrate of FYN raises the interesting possibility that Sirm
may participate in adipocyte-specific functions of FYN.
The binding of Sirm to Grb-2 is also consistent with the
known specificity of the Grb-2 SH3 binding domain (Fig. 2B)
(28). The dissociation of Sirm from Grb-2 follows the same time
course and dose responsiveness as insulin-induced dissociation
of Grb-2 from son-of-sevenless (29, 30). This dissociation has
been invoked as a possible mechanism underlying the transient
nature of insulin’s effect to activate Ras. By analogy, one could
envision that Sirm links Grb-2 to downstream effectors and
that this effect is lost upon prolonged insulin stimulation.
The evidence presented in this paper indicates that Sirm is a
novel adapter protein, which can function in a variety of cell
types by binding the Src family kinase FYN and Grb-2. Sirm
expression appears to correlate with the ability of organs and
cells to respond to insulin, and several of the intracellular
targets of Sirm have been implicated in signaling downstream
of the insulin receptor. We would like to tentatively propose
that Sirm plays a role in modulating insulin action in insulin-
sensitive tissues via its association with signaling molecules.
Further studies required to conclusively test this hypothesis
are under way.
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